These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 21273704)

  • 1. Modifiers and mechanisms of multi-system polyglutamine neurodegenerative disorders: lessons from fly models.
    Mallik M; Lakhotia SC
    J Genet; 2010 Dec; 89(4):497-526. PubMed ID: 21273704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of pathways controlling toxicity in the eye and brain in Drosophila models of human neurodegenerative diseases.
    Ghosh S; Feany MB
    Hum Mol Genet; 2004 Sep; 13(18):2011-8. PubMed ID: 15254017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modifier pathways in polyglutamine (PolyQ) diseases: from genetic screens to drug targets.
    Costa MD; Maciel P
    Cell Mol Life Sci; 2022 May; 79(5):274. PubMed ID: 35503478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AQAMAN, a bisamidine-based inhibitor of toxic protein inclusions in neurons, ameliorates cytotoxicity in polyglutamine disease models.
    Hong H; Koon AC; Chen ZS; Wei Y; An Y; Li W; Lau MHY; Lau KF; Ngo JCK; Wong CH; Au-Yeung HY; Zimmerman SC; Chan HYE
    J Biol Chem; 2019 Feb; 294(8):2757-2770. PubMed ID: 30593503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear accumulation of polyglutamine disease proteins and neuropathology.
    Havel LS; Li S; Li XJ
    Mol Brain; 2009 Jul; 2():21. PubMed ID: 19575804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polyglutamine expansion diseases: failing to deliver.
    Morfini G; Pigino G; Brady ST
    Trends Mol Med; 2005 Feb; 11(2):64-70. PubMed ID: 15694868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanded polyglutamine domain possesses nuclear export activity which modulates subcellular localization and toxicity of polyQ disease protein via exportin-1.
    Chan WM; Tsoi H; Wu CC; Wong CH; Cheng TC; Li HY; Lau KF; Shaw PC; Perrimon N; Chan HY
    Hum Mol Genet; 2011 May; 20(9):1738-50. PubMed ID: 21300695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant E2F activation by polyglutamine expansion of androgen receptor in SBMA neurotoxicity.
    Suzuki E; Zhao Y; Ito S; Sawatsubashi S; Murata T; Furutani T; Shirode Y; Yamagata K; Tanabe M; Kimura S; Ueda T; Fujiyama S; Lim J; Matsukawa H; Kouzmenko AP; Aigaki T; Tabata T; Takeyama K; Kato S
    Proc Natl Acad Sci U S A; 2009 Mar; 106(10):3818-22. PubMed ID: 19237573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein transduction domain-mediated delivery of QBP1 suppresses polyglutamine-induced neurodegeneration in vivo.
    Popiel HA; Nagai Y; Fujikake N; Toda T
    Mol Ther; 2007 Feb; 15(2):303-9. PubMed ID: 17235308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome-wide screen for modifiers of ataxin-3 neurodegeneration in Drosophila.
    Bilen J; Bonini NM
    PLoS Genet; 2007 Oct; 3(10):1950-64. PubMed ID: 17953484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p62 plays a protective role in the autophagic degradation of polyglutamine protein oligomers in polyglutamine disease model flies.
    Saitoh Y; Fujikake N; Okamoto Y; Popiel HA; Hatanaka Y; Ueyama M; Suzuki M; Gaumer S; Murata M; Wada K; Nagai Y
    J Biol Chem; 2015 Jan; 290(3):1442-53. PubMed ID: 25480790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studying polyglutamine diseases in Drosophila.
    Xu Z; Tito AJ; Rui YN; Zhang S
    Exp Neurol; 2015 Dec; 274(Pt A):25-41. PubMed ID: 26257024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conformational changes and aggregation of expanded polyglutamine proteins as therapeutic targets of the polyglutamine diseases: exposed beta-sheet hypothesis.
    Nagai Y; Popiel HA
    Curr Pharm Des; 2008; 14(30):3267-79. PubMed ID: 19075705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila.
    Nagai Y; Fujikake N; Ohno K; Higashiyama H; Popiel HA; Rahadian J; Yamaguchi M; Strittmatter WJ; Burke JR; Toda T
    Hum Mol Genet; 2003 Jun; 12(11):1253-9. PubMed ID: 12761040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of ter94, Drosophila VCP, as a modulator of polyglutamine-induced neurodegeneration.
    Higashiyama H; Hirose F; Yamaguchi M; Inoue YH; Fujikake N; Matsukage A; Kakizuka A
    Cell Death Differ; 2002 Mar; 9(3):264-73. PubMed ID: 11859409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new role for microRNA pathways: modulation of degeneration induced by pathogenic human disease proteins.
    Bilen J; Liu N; Bonini NM
    Cell Cycle; 2006 Dec; 5(24):2835-8. PubMed ID: 17172864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic modifiers of age-at-onset in polyglutamine diseases.
    Chen Z; Sequeiros J; Tang B; Jiang H
    Ageing Res Rev; 2018 Dec; 48():99-108. PubMed ID: 30355507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RACK1 modulates polyglutamine-induced neurodegeneration by promoting ERK degradation in Drosophila.
    Xie J; Han Y; Wang T
    PLoS Genet; 2021 May; 17(5):e1009558. PubMed ID: 33983927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNAi for the large non-coding hsromega transcripts suppresses polyglutamine pathogenesis in Drosophila models.
    Mallik M; Lakhotia SC
    RNA Biol; 2009; 6(4):464-78. PubMed ID: 19667761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptional repression and cell death induced by nuclear aggregates of non-polyglutamine protein.
    Fu L; Gao YS; Sztul E
    Neurobiol Dis; 2005 Dec; 20(3):656-65. PubMed ID: 15964198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.